This article is more than 5 years old. Information may no longer be current.
ThromboGenics completes phase 2b trial enrollment of microplasmin in vitrectomy
LEUVEN, Belgium — ThromboGenics has completed patient enrollment for its phase 2b MIVI III trial in the United States, which is evaluating the safety and efficacy of microplasmin in vitrectomy, the company announced in a press release.
Microplasmin is a proteolytic enzyme that cleaves molecules linking the vitreous to the retina. Thus, the drug may have the potential to facilitate vitrectomy and induce posterior vitreous detachment without the risks inherent to surgical detachment.
The MIVI III trial (Microplasmin for Vitreous Injection) is a randomized, double-masked, placebo-controlled study involving 120 vitrectomy patients at 19 sites. Investigators are evaluating three doses of the drug — 25 µg, 75 µg and 125 µg — vs. placebo, assessing the safety and efficacy of intravitreal injections 7 days before vitrectomy.
The company expects to have unmasked results of the trial in June.